You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Combinatorial RXR-based therapeutics for Alzheimer's disease

    SBC: REXCEPTOR, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): The principle objective of this application is the development of safer and more effective combinatorial therapy for AD. ReXceptor, Inc. is developing new therapeutics for the treatment of AD based on stimulating the physiological clearance mechanisms of soluble forms of A from the brain. Bexarotene is an agonist of the ligand-activated transcription factor, r ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of VPL Vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Project Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Feasibility of Non-surgical Implant Adjustment

    SBC: Apto Orthopaedics Corportation            Topic: NIAMS

    DESCRIPTION (provided by applicant): While minimally invasive surgery has transformed the practice of surgery, access to implants for removal or alteration still requires surgery which generates risk and high cost. A next-generation approach is non-invasive, where implants are adjusted without an incision. There are clear applications in all fields of surgery, but particulary in orthopaedics wher ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Small Molecule Therapeutics for Pancreatic Cancer

    SBC: ChemRegen Inc            Topic: NCI

    Project Summary/Abstract Developing new ways to treat pancreatic cancer is a significant challenge. Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and results in an estimated 37,000 deaths/year. Pancreatic cancer therapeutic options are limited to surgery and/or combinations of chemotherapy and radiation. Unfortunately, late-stage diagnosis of pancreat ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Ex vivo purging strategy for treatment of multiple myeloma

    SBC: DNATRIX INC            Topic: NCI

    DESCRIPTION (provided by applicant): The ultimate goal of this application is to develop a novel ex vivo purging method using myxoma virus (MYXV), a rabbit-specific poxvirus, to improve the clinical outcomes in treatment of multiple myeloma (MM). MM is aclonal plasma cell malignancy that has to date resisted essentially all therapeutic strategies. Currently, the standard of care for patients wit ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. ChemoFilter: A Novel Catheter Device to Enable High-Dose Chemotherapy Treatment

    SBC: CHEMOFILTER, INC.            Topic: NCI

    Project Summary: Intravenous dosing of drugs for applications ranging from cancer chemotherapy to anti-microbials to lytic (blood clot dissolving) agents is limited by systemic toxicity. Currently, the only ways to remove drugs from the blood are throughnatural metabolism or costly impractical measures such as dialysis. Despite intense focus on targeted drug delivery agents, these therapies are c ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema

    SBC: ADEPTHERA, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Destruction of lymphatic vessels during the treatment of breast cancer by surgery and/or radiation therapy can lead to the development of secondary lymphedema. The breast-cancer-related lymphedema is associated with debilitating limb swelling, chronic inflammation, tissue fibrosis, and increased susceptibility to infection. It has been estimated that approximat ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Intra-procedure Deformable Ultrasound-MRI Fusion for Prostate Biopsies

    SBC: ZMK Medical Technologies, Inc.            Topic: NCI

    This proposal is a collaborative effort between Yale University and the medical device company Eigen to develop a more robust and accurate method for the deformable fusion of pre-operative magnetic resonance images (MRI) and intra-procedure trans-rectal ultrasound (TRUS) images to guide prostate biopsy. Prostate cancer is a major cause of death in the U.S. and biopsy is the gold-standard for its d ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Validation of a Novel Treatment for Glioblastoma

    SBC: CURTANA PHARMACEUTICALS INC            Topic: NCI

    ? DESCRIPTION (provided by applicant): The goal of this application is to study in vivo efficacy of CT102, a newly discovered inhibitor of the OLIG2 transcription factor in animal models of glioblastoma (GBM), a highly underserved area of pharmacotherapy. In this proposal, the experienced drug discovery group at Curtana Pharmaceuticals Inc. will conduct a pre-clinical evaluation of selectivity ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting of Myc-Max dimerization for the treatment of cancer

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Myc is a key transcriptional regulator due to its critical role in many fundamental cellular processes, such as cell cycle progression and cell growth. Therefore, dysregulation of Myc expression can lead to disease, including cancer. Myc is overexpressed in many human tumors, and it is estimated that 1 in 7 cancer deaths in the United States are resultant of hi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government